tbuckley/cabot-search huggingface dataset:
OP0335 THE 11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR SPI-62 DIFFERENTIALLY MODULATES PREDNISOLONE IMMUNE AND MUSCULOSKELETAL EFFICACY AND BONE FORMATION/RESORPTION BIOMARKERS IN PATIENTS WITH POLYMYALGIA RHEUMATICA (PMR): AN INTERIM REPORT
Authors: D. A. Katz, F. Buttgereit, A. Everding, I. Andreica, H. L. Kellner, F. Schuch, T. K. Marmon, F. S. Czerwiec, K. Desai
Journal: Annals of the Rheumatic Diseases (2024)
POS1309 MYOCARDITIS IN IDIOPATHIC INFLAMMATORY MYOPATHIES: A COMPREHENSIVE ANALYSIS OF RISK FACTORS AND PROGNOSTIC OUTCOMES
Authors: J. Álvarez Troncoso, C. A. Siccha Sinti, E. Ramirez Vicente, H. J. Bermeo Vera, S. Carrasco Molina, S. Gil Garrote, P. Nozal Aranda, Á. Robles Marhuenda, A. Noblejas Mozo, C. Soto Abánades, E. Martínez Robles, J. J. Ríos Blanco
Journal: Annals of the Rheumatic Diseases (2024)
POS1412 INCIDENCE, PREVALENCE, AND BASELINE CHARACTERISTICS OF PRIMARY AND SECONDARY RAYNAUD’S PHENOMENON IN THE UNITED KINGDOM, 2000-2022: A POPULATION-BASED COHORT STUDY
Authors: F. Dernie, A. Prats-Uribe, W. Y. Man, A. Delmestri, D. Prieto-Alhambra
Journal: Annals of the Rheumatic Diseases (2024)
POS1155 STUDY OF LNCRNAS INVOLVED IN THE DIFFERENT RESPONSE TO BIOLOGICAL DRUGS IN PSORIATIC ARTHRITIS PATIENTS: EXPRESSION PROFILE AND GENOMIC VARIABILITY
Authors: M. S. Chimenti, A. D’antonio, G. De Benedittis, A. Latini, C. Morgante, P. Conigliaro, P. Triggianese, A. Bergamini, G. Novelli, C. Ciccacci, P. Borgiani
Journal: Annals of the Rheumatic Diseases (2024)
AB0482 PREVALENCE AND SEVERITY OF MAFLD IN PSORIATIC DISEASE: ARE WE MISSING SOMETHING?
Authors: N. Vegas-Revenga, I. Urionaguena-Onaindia, N. Plaza-Aulestia, B. Sampedro Andrada, C. San Juan-López, V. Morillo-Montañés, O. Ibarguengoitia-Barrena, I. Calvo-Zorilla, D. Montero-Seisdedos, L. Vega-Álvarez, A. Fernández-Undabarrena, J. F. Garcia Llorente
Journal: Annals of the Rheumatic Diseases (2024)
POS0577 LONG-TERM BONE MINERAL DENSITY CHANGES IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH DENOSUMAB: QUASI-EXPERIMENTAL STUDY
Authors: A. Fassio, F. Pollastri, S. Andreola, D. Gatti, M. Gatti, G. Gambaro, P. M. Ferraro, M. Rossini, O. Viapiana, R. Bixio, G. Adami
Journal: Annals of the Rheumatic Diseases (2024)
POS1308 DERMATOMYOSITIS ASSESSMENT OF RASH VIA TELEMEDICINE (DART)
Authors: N. Pongtarakulpanit, T. Chandra, S. Dzanko, E. Gkiaouraki, S. Keret, R. Lomanto Silva, S. Sriram, D. Saygin, V. Liarski, D. Ascherman, C. V. Oddis, S. Moghadam-Kia, R. Aggarwal
Journal: Annals of the Rheumatic Diseases (2024)
AB0391 CLINICAL ASSOCIATIONS OF MYOSITIS AND SYSTEMIC SCLEROSIS IMMUNOBLOTS SPECIFICITIES IN AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASE: DATA OF 203 PATIENTS FROM A NATIONAL REFERRAL CENTER
Authors: B. Atienza-Mateo, M. Renuncio-García, A. Serrano-Combarro, J. Irure-Ventura, J. M. Cifrián-Martínez, M. López Hoyos, R. Blanco
Journal: Annals of the Rheumatic Diseases (2024)
POS0984 COMPARISON OF ON-LABEL TREATMENT PERSISTENCE IN REAL-WORLD PATIENTS WITH PSORIATIC ARTHRITIS RECEIVING GUSELKUMAB VERSUS SUBCUTANEOUS IL-17A INHIBITORS
Authors: N. J. Shiff, P. J. Mease, R. Zhao, S. Ferrante, S. D. Chakravarty, J. A. Walsh
Journal: Annals of the Rheumatic Diseases (2024)
POS0789 CHARACTERIZATION OF CIRCULATING CHONDROGENIC MESENCHYMAL STEM CELLS IN EROSIVE HAND OSTEOARTHRITIS: IMPLICATIONS FOR CHONDROCYTE HYPERTROPHY, APOPTOSIS, AND AUTOPHAGY
Authors: G. Buoncuore, C. Barbati, E. Balbinot, F. M. Ucci, C. Ciancarella, F. Ceccarelli, S. Scarpa, A. I. Celia, G. Tripodi, A. Scorda, C. Alessandri, F. Conti
Journal: Annals of the Rheumatic Diseases (2024)
POS0552 CYTOTOXIC CD8+ T CELLS REGULATE PRO-FIBROTIC MYOFIBROBLAST ACTIVITY VIA JAK/STAT3 AND TGFΒ SIGNALING IN AUTO-IMMUNE CONNECTIVE TISSUE DISEASE PATHOLOGY
Authors: T. I. Papadimitriou, D. Dorst, P. Van der Kraan, M. Koenders, R. M. Thurlings, A. Van Caam
Journal: Annals of the Rheumatic Diseases (2024)
AB0362 OSTEOPOROSIS AND OTHER EPIDEMIOLOGICAL FACTORS LINKED TO HIP FRACTURES IN A SOUTH AMERICAN COHORT
Authors: J. L. Vargas Rojas, L. A. Dulcey Sarmiento, J. Gomez Ayala, M. C. Amaya Muñoz, J. S. Theran Leon, N. Moreno Guerra, A. P. Lizcano Manrique
Journal: Annals of the Rheumatic Diseases (2024)
POS1376 AUTOMATIC SEGMENTATION-FREE INFLAMMATION SCORING IN RHEUMATOID ARTHRITIS FROM MRI USING DEEP LEARNING
Authors: Y. LI, D. Shamonin, T. Hassanzadeh, D. A. Ton, M. Reijnierse, A. H. M. Van der Helm – van Mil, B. Stoel
Journal: Annals of the Rheumatic Diseases (2024)
POS1085 UNDERSTANDING AGE AS A RISK FACTOR FOR COMPLICATIONS AFTER TOTAL KNEE ARTHROPLASTY: WHAT CAN WE LEARN FROM MACHINE LEARNING?
Authors: B. Mehta, Y. Yuan, C. Heiting, K. Ho, S. Goodman, P. Sculco, F. Wang, S. Ibrahim, P. Cram, R. Caruna
Journal: Annals of the Rheumatic Diseases (2024)
POS0723 THE PREDICTIVE POTENTIAL OF NOVEL ANTIBODY BIOMARKERS IN DETERMINING FIRST-LINE THERAPY RESPONSE IN RHEUMATOID ARTHRITIS
Authors: S. Fadlallah, P. Vandormael, P. Ruytinx, A. Pues, E. Sleurs, J. Liesenborgs, J. Joly, A. Agten, F. Vandenabeele, J. Fraussen, P. Verschueren, V. Somers
Journal: Annals of the Rheumatic Diseases (2024)
AB0416 BIMEKIZUMAB IMPACT ON CARDIOVASCULAR INFLAMMATION MARKERS IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM PHASE 3 TRIALS
Authors: G. Kokolakis, R. B. Warren, R. G. Langley, B. Kirby, J. G. Krueger, K. Eyerich, L. Davis, O. Davies, N. Cross, D. Deherder, B. Strober
Journal: Annals of the Rheumatic Diseases (2024)
POS0982 APREMILAST REDUCES AXIAL INFLAMMATION IN PATIENTS WITH PSORIATIC ARTHRITIS AS ASSESSED BY CANDEN MRI SCORING: RESULTS FROM THE PHASE 4 MOSAIC STUDY
Authors: M. Østergaard, W. P. Maksymowych, R. G. Lambert, M. Boesen, G. Valenzuela, M. Bubb, O. Kubassova, X. Baraliakos, C. Selmi, S. Colgan, Y. Klyachkin, C. Deignan, Z. Zhou, P. J. Mease
Journal: Annals of the Rheumatic Diseases (2024)
POS1158 PEX5 ACTS AS A NEGATIVE REGULATOR OF RANKL-INDUCED OSTEOCLASTOGENESIS IN VITRO AND INFLAMMATORY CALVARIAL BONE DESTRUCTION IN VIVO
Authors: C. H. Chung, C. H. Lee, S. Y. Eun, Y. H. Cheon, G. D. Park, J. Y. Kim, M. S. Lee
Journal: Annals of the Rheumatic Diseases (2024)
AB0352 EFFECT OF ORAL VITAMIN K2 USE ON KNEE OSTEOARTHRITIS PROGRESSION IN AN EXPERIMENTALLY CREATED OSTEOARTHRITIS MODEL IN RATS
Authors: E. Uzun, I. Tekeoğlu, Ö. Budak, H. Cakiroglu, E. Şahin, K. Nas, A. Kamanli
Journal: Annals of the Rheumatic Diseases (2024)
POS1209 TELOMERES IN RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE
Authors: P. Conigliaro, A. Latini, C. Bonini, G. De Benedittis, A. D’antonio, B. Kroegler, C. Ciccacci, A. Bergamini, P. Borgiani, M. S. Chimenti
Journal: Annals of the Rheumatic Diseases (2024)
AB0286 LONG-TERM EFFECTS OF WEIGHT RESTORATION ON BONE MINERAL DENSITY (BMD) IN PATIENTS WITH ANOREXIA NERVOSA
Authors: G. Adami, A. Fassio, C. Simona, M. Molgora, M. Chimini, B. Segattini, D. Gatti, M. Rossini, A. Dalle Grave, R. Dalle Grave
Journal: Annals of the Rheumatic Diseases (2024)
AB0347 30 DAYS READMISSIONS OF OSTEOARTHRITIS AND INDEPENDENT PREDICTORS: INSIGHTS FROM NATIONAL READMISSION DATABASE
Authors: V. Jelic, S. Piplani, V. R. Bejugam, S. Kong, S. T. Kolli, G. Jelic, P. K. Komminni, S. R. Goguri, P. Mogga, M. Radulovic, M. Vukelic
Journal: Annals of the Rheumatic Diseases (2024)
AB0351 DISTRIBUTION OF CARTILAGE, SUBCHONDRAL BONE, TRABECULAR BONE, AND BONE MARROW HISTOPATHOLOGY SCORES ACROSS THE MOST AND LEAST DAMAGED AREAS IN KNEE OSTEOARTHRITIS
Authors: B. Mehta, M. Otero, A. M. Malfait, D. Mintz, S. Goodman, T. Pannellini, P. Sculco, J. Rodriguez, M. Figgie, S. Cushing, C. Heiting, E. Spoloare, E. Dicarlo, D. Orange
Journal: Annals of the Rheumatic Diseases (2024)
AB0414 USEFULNESS OF THE DETERMINATION OF SPHINGOSINE-1-PHOSPHATE (S1P) AND ITS RECEPTOR (S1PR) AS A BIOMARKER AND PREDICTOR OF DAMAGE AND INFLAMMATION IN PATIENTS WITH PSORIATIC ARTHRITIS (PsA)
Authors: D. Ruiz-Montesino, D. V. Mendoza Mendoza, C. Dominguez, J. Bocio, M. J. Montoya García, M. Giner García, M. A. Vázquez Gómez, J. J. Pérez Venegas
Journal: Annals of the Rheumatic Diseases (2024)
Performance and Interpretation of Lung Scintigraphy
Authors: Romain Le Pennec, Wolfgang Schaefer, Mark Tulchinsky, François Lamoureux, Paul Roach, Christoph Rischpler, Katherine Zukotynski, Christopher O’Brien, Declan Murphy, Pierre Pascal, Grégoire Le Gal, Pierre-Yves Salaun, Pierre-Yves Le Roux
Journal: Clinical Nuclear Medicine (2024)

Purpose Although ventilation/perfusion (V/Q) scintigraphy is a widely used imaging test, different options are possible for the acquisition and interpretation of the scan. The aim of this study was to assess current practices regarding the use and interpretation of lung scintigraphy in various clinical indications. Patients and Methods An online survey comprising 25 questions was sent to nuclear medicine departments in Australia, Canada, France, Germany, and United States between 2022 and 2023. A single response per department was consolidated. Results Four hundred nineteen responses were collected (Australia: 32, Canada: 58, France: 149, Germany: 92, and United States: 88). For acute pulmonary embolism (PE) diagnosis, 82.8% of centers reported using SPECT acquisitions (Australia: 93.3%, Canada: 91.8%, France: 99.2%, Germany: 96.2%, and United States: 32.1%). Among them, SPECT images were combined with a CT scan in 70.5% of centers. A total of 10.6% of centers reported not using ventilation for acute PE diagnosis. SPECT acquisition was used in 97.8% of centers using 99m Tc carbon particles, 97.1% 81m Kr gas, 58.7% 99m Tc-DTPA, and 19.4% 133 Xe gas, respectively. For V/Q SPECT interpretation, the EANM criteria were used in 65.0% of departments. A very wide variety of practices were observed in pregnant women and in COVID-19 patients. SPECT acquisition was widely used in the follow-up of PE and for the screening of chronic thromboembolic pulmonary hypertension (&gt;90% of centers), with inconsistency regarding the interpretation of matched perfusion defects in this setting. Conclusions This survey shows the strong adoption of SPECT in the various clinical indications of lung scintigraphy, except in the United States, where planar imaging is still mostly used. The survey also shows variability in interpretation criteria both for PE diagnosis and screening for chronic thromboembolic pulmonary hypertension, highlighting the need for further standardizations of practices.
POS1069 ARTIFICIAL INTELLIGENCE MODEL FOR SEGMENTATION AND SEVERITY SCORING OF OSTEOPHYTES IN HAND OSTEOARTHRITIS ON ULTRASOUND IMAGES
Authors: B. Schultz Overgaard, A. Bossel Holst Christensen, L. Terslev, T. R. Savarimuthu, S. A. Just
Journal: Annals of the Rheumatic Diseases (2024)
Risk Factors for Rapid Cognitive Decline in Amyloid-Negative Individuals Without Cognitive Impairment or With Early-Stage Cognitive Loss in Screening Tests
Authors: Yong-Jin Park, Joon Young Choi, Kyung-Han Lee, Sang Won Seo, Seung Hwan Moon
Journal: Clinical Nuclear Medicine (2024)

Purpose Although rapid cognitive decline (RCD) is an important unfavorable prognostic factor, not much is known about it, especially in amyloid-negative individuals. The purpose of this study was to investigate risk factors for RCD in amyloid-negative individuals. Patients and Methods We retrospectively enrolled 741 individuals who were either cognitively unimpaired or had early-stage cognitive ability loss and who underwent 18 F-florbetaben (FBB) (n = 402) or 18 F-flutemetamol (FMM) (n = 339) PET/CT. Based on visual and semiquantitative (SUV ratio [SUVR]–based) analysis, the following amyloid-negative groups were established: visual-negative FBB (n = 232), visual-negative FMM (n = 161), SUVR-negative FBB (n = 104), and SUVR-negative FMM (n = 101). Univariable and multivariable logistic regression analyses were performed for RCD using 5 SUVRs, 5 cortical thicknesses, and 5 neuropsychological domains and clinico-demographic factors. Results In the amyloid-negative groups, a decline in language function was commonly identified as a significant risk factor for RCD ( P = 0.0044 in the visual-negative FBB group, P = 0.0487 in the visual-negative FMM group, P = 0.0031 in the SUVR-negative FBB group, and P = 0.0030 in the SUVR-negative FMM group). In addition, declines in frontal/executive function, frontal SUVR, and parietal SUVR; a longer duration of education; and mild cognitive decline in the amyloid-negative groups were also significant risk factors for RCD. Conclusions Even in amyloid-negative individuals without cognitive impairment or with early-stage cognitive ability loss, those with decreased language and frontal/executive functions on neuropsychological testing are at risk of progression to RCD.
POS0722 PURIFIED MONOCLONAL RHEUMATOID FACTORS BIND FC CONTAINING TNF INHIBITORS IN VITRO BUT NOT THE FC-FREE TNF INHIBITOR, CERTOLIZUMAB PEGOL
Authors: S. Bidgood, D. Kallenberg, A. Turner, J. O’neill, G. Odede, K. Mikula, J. Zydron, H. Hailu, E. Lukijanczuk, S. Cross, K. Tyson, S. Heywood, C. Cara, B. Lauwerys, B. Ufuktepe, D. Humphreys, A. Shock
Journal: Annals of the Rheumatic Diseases (2024)
AB0399 ANALYSIS OF SERUM BIOMARKERS IN THE DIAGNOSIS AND MONITORING OF DISEASE ACTIVITY IN PSORIATIC ARTHRITIS
Authors: S. Sundanum, V. Marzaioli, D. Anton, H. Darcy, P. Gallagher, C. Orr, U. Fearon, D. Veale
Journal: Annals of the Rheumatic Diseases (2024)
AB0480 EARLY FATIGUE IMPROVEMENT WITH GUSELKUMAB ASSOCIATES WITH LONGER TERM DISEASE CONTROL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REPORTING SUBSTANTIAL FATIGUE: POST HOC ANALYSES OF A SUB-POPULATION OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF GUSELKUMAB IN BIOLOGIC-NAÏVE PATIENTS
Authors: N. J. Shiff, D. D. Gladman, X. Baraliakos, M. Starr, R. Ranza, E. Rampakakis, F. Nantel, C. Han, A. Östör, P. J. Mease
Journal: Annals of the Rheumatic Diseases (2024)
OP0035 RISK OF FRAGILITY FRACTURE AFTER LONG-TERM DISCONTINUATION OF OSTEOPOROSIS TREATMENT IN POST-MENOPAUSAL OSTEOPOROSIS WOMEN IN FRANCE: A POPULATION-BASED STUDY CONDUCTED ON THE NATIONWIDE CLAIM DATABASE (SNDS)
Authors: M. Laborey, M. Benmerad, A. Lajoinie, P. Samama, G. Désaméricq, L. Chelbani, K. Briot
Journal: Annals of the Rheumatic Diseases (2024)
AB0527 THE ASSOCIATION BETWEEN DIFFERENT ARTICULAR MANIFESTATIONS REPORTED BY PATIENTS OR RECORDED AT CLINICAL EXAMINATION AND MAGNETIC RESONANCE IMAGING - INFLAMMATION IN HANDS OF RHEUMATOID ARTHRITIS PATIENTS AT SELF-REPORTED FLARES
Authors: D. Kuettel, D. Glinatsi, M. Østergaard, J. Primdahl, L. Terslev, A. Pedersen, U. Weber, K. Hørslev-Petersen
Journal: Annals of the Rheumatic Diseases (2024)
CXCR4-Targeted 68Ga-Pentixafor PET/CT Imaging in Inflammatory Bowel Disease
Authors: Yang Chen, Hui Yuan, Xiaoyue Tan, Yuxiang Shang, Xiaolin Sun, Peng Wang, Lei Jiang
Journal: Clinical Nuclear Medicine (2024)

Purpose To investigate the role of CXCR4-targeted 68 Ga-pentixafor PET/CT imaging in inflammatory bowel disease (IBD). Methods Five IBD patients and 12 control subjects performing 68 Ga-pentixafor PET/CT examinations were included. 68 Ga-pentixafor PET/CT imaging and endoscopic findings were recorded and compared. The semiquantitative parameters of 68 Ga-pentixafor uptake by the lesion segments in IBD patients and the normal intestines in the control were investigated. Results Among these 5 IBD patients, endoscopy successfully examined a total of 26 intestinal segments, with 13 segments showing endoscopic lesions. 68 Ga-pentixafor PET/CT was positive in all endoscopy-proven lesions (13/13). Additionally, 68 Ga-pentixafor PET/CT revealed the lesions in small intestines and colons that cannot be reached by endoscopy due to severe stenosis, and mesenteric lymphadenitis accompanied IBD. The SUV max of the lesion segments in IBD patients was significantly higher than that of the normal intestines in the control group (median, 3.15 [range, 1.61–6.26] vs 1.67 [1.18–2.29], P &lt; 0.001). Moreover, the SUV max ratios of the lesion segments/liver or blood pool were higher when compared with the control (2.20 [1.13–3.26] vs 0.85 [0.54–1.20]; 1.66 [0.94–2.95] vs 0.67 [0.52–1.04]; P ≤ 0.001). Conclusion 68 Ga-pentixafor PET/CT can be a potentially valuable tool to assess the active intestinal lesions of IBD with high sensitivity. Moreover, this noninvasive approach does not require fasting or bowel preparation, offering good tolerance and safety.
AB0528 THERAPEUTIC EFFECACY OF JAK INHIBITORS WITH OR WITHOUT METHOTREXATE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: T. Okano, C. Yoshimura, K. Mamoto, Y. Yamada, T. Kojima, K. Inui, M. Tada, K. Orita, S. Anno, T. Iida, T. Koike
Journal: Annals of the Rheumatic Diseases (2024)
AB0415 SIGNIFICANT REDUCTION OF ABDOMINAL FAT WITH APREMILAST TREATMENT IN PATIENTS WITH PSORIATIC ARTHRITIS
Authors: B. Dijkshoorn, F. Coban, E. Van Geel, R. Hansildaar, R. Bos, F. Reimann, M. Korteweg, M. Nurmohamed
Journal: Annals of the Rheumatic Diseases (2024)
The Contribution of 68Ga-FAPI-04 PET/CT to Staging and Prognosis in Gastric Cancer
Authors: Ediz Beyhan, Tevfik Fikret Çermik, Özge Erol Fenercioğlu, Rahime Şahin, Göksel Alçin, Tamer Aksoy, Esra Arslan, Nurhan Ergül
Journal: Clinical Nuclear Medicine (2024)

This study aimed to compare the diagnostic capabilities of 18 F-FDG PET/CT and 68 Ga-FAPI-04 PET/CT imaging in staging gastric carcinoma, exploring the impact of 68 Ga-FAPI-04 PET/CT on treatment planning and its prognostic significance.
Prognostic Value of Bone Scintigraphy in Cardiac Amyloidosis
Authors: Sang-Geon Cho, Sangwon Han
Journal: Clinical Nuclear Medicine (2024)

Objectives The prognostic value of bone scintigraphy in cardiac amyloidosis (CA) remains undetermined. We conducted a systematic review and meta-analysis on the association of cardiac uptake on bone scintigraphy with mortality in known or suspected CA. Patients and Methods PubMed, Embase, and Cochrane library databases were searched up to November 2023 for studies that evaluated cardiac uptake on bone scintigraphy as a prognostic factor in the workup of CA. Hazards ratios (HRs) of high cardiac uptake for outcomes of all-cause or cardiac death were pooled and analyzed with stratifications according to the study populations, analytical methodologies, and radiotracers. Results Fourteen studies (3325 patients) were finally included. In studies regarding known or suspected CA, visual grades were not prognostically significant, regardless of the threshold used, with pooled HRs of 2.25 (95% confidence interval [CI], 0.93–5.48), 1.55 (95% CI, 0.89–2.68), and 1.53 (95% CI, 0.95–2.47) for visual grades ≥1, ≥2, and ≥3, respectively. By contrast, high cardiac uptake on semiquantitative measurements (heart-to-contralateral lung ratio, n = 6; heart-to-whole-body ratio, n = 1) was associated with increased mortality (pooled HR = 2.27 [95% CI, 1.87–2.76] for all semiquantitative measurements; 2.26 [1.86–2.74] for heart-to-contralateral lung ratio only). No difference in prognostic significance was found across 3 different 99m Tc-radiotracers ( P = 0.619). However, high cardiac uptake was not predictive of mortality in aortic stenosis-related CA (pooled HR = 1.13 [95% CI, 0.96–1.32]). Conclusions High semiquantitative cardiac uptake on bone scintigraphy is associated with an increased risk of mortality in patients with known or suspected CA.
POS0969 BIMEKIZUMAB-TREATED PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS SHOWED SUSTAINED ACHIEVEMENT OF MINIMAL DISEASE ACTIVITY AND REMISSION: UP TO 2-YEAR RESULTS FROM TWO PHASE 3 STUDIES
Authors: L. C. Coates, L. E. Kristensen, A. Ogdie, W. Tillett, B. Ink, N. Goldammer, R. Bajracharya, J. Coarse, A. M. Orbai
Journal: Annals of the Rheumatic Diseases (2024)
POS0591 ARE THERE SEX DIFFERENCES IN RISK AND OUTCOMES OF STROKE IN PATIENTS WITH RHEUMATOID ARTHRITIS? A POPULATION-BASED RETROSPECTIVE COHORT STUDY
Authors: E. Myasoedova, R. Lennon, S. Achenbach, E. Scharf, C. Oakley, R. Kumar, R. George, A. Lopez-Ruiz, J. M. Davis, M. Vassilaki, P. Vemuri, C. S. Crowson
Journal: Annals of the Rheumatic Diseases (2024)
AB0523 CAN EYE-TRACKING HELP TO CREATE A NEW METHOD FOR X-RAY ANALYSIS OF RHEUMATOID ARTHRITIS PATIENTS, INCLUDING JOINT SEGMENTATION AND SCORING METHODS?
Authors: A. Saraux, B. Quere, L. Meneur, N. Foulquier, H. Pensec, F. Garrigues, V. Devauchelle-Pensec
Journal: Annals of the Rheumatic Diseases (2024)
POS0630 THE FREQUENCY OF LONG-TERM ROUTINE LABORATORY TOXICITY MONITORING IN RHEUMATOID ARTHRITIS PATIENTS USING DISEASE MODIFYING ANTI-RHEUMATIC DRUGS CAN BE VASTLY REDUCED: A LARGE LONG-TERM COHORT STUDY
Authors: E. Ulijn, N. Den Broeder, R. Landewé, K. Bevers, N. Van Herwaarden, A. A. Den Broeder
Journal: Annals of the Rheumatic Diseases (2024)
POS1088 DEVELOPMENT OF THE SPIDER, A MULTISYSTEMIC SYMPTOM IMPACT TOOL FOR PEOPLE WITH HYPERMOBILITY RELATED CONDITIONS. AN INITIAL VALIDATION WITH ADULTS
Authors: E. Ewer, H. Kazkaz, R. De Pauw, P. Rowe, N. Ninis, I. De Wandele, J. Simmonds
Journal: Annals of the Rheumatic Diseases (2024)
AB0396 MODULATION OF PERIPHERAL BLOOD T AND INNATE LYMPHOCYTES BY APREMILAST IN PATIENTS WITH PSORIATIC ARTHRITIS AND CLINICAL THERAPEUTIC RESPONSE
Authors: M. De Santis, A. Tonutti, F. Motta, N. Isailovic, A. Ceribelli, G. M. Guidelli, M. Caprioli, D. Renna, N. Luciano, C. Selmi
Journal: Annals of the Rheumatic Diseases (2024)
POS1232 NEUROINFLAMMATION IN AN EXPERIMENTAL MODEL OF ARTHRITIS: A PILOT STUDY
Authors: N. Garcia Dos Santos, B. Bartikoski, T. E. Karnopp, R. Cavalheiro Do Espírito Santo, V. Da Silva Freitas, G. Flores Chapacais, M. L. Gasparini, S. Pilotti, I. Da Silva Torres, R. Machado Xavier
Journal: Annals of the Rheumatic Diseases (2024)
POS1037 THE CLINICAL EFFICACY OF INHIBITORS OF INTERLEUKIN-6 RECEPTOR AND JANUS KINASE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: K. Mamoto, T. Okano, Y. Yamada, T. Kojima, S. Anno, K. Orita, T. Iida, M. Tada, K. Inui, T. Koike, H. Nakamura
Journal: Annals of the Rheumatic Diseases (2024)
AB0472 EFFICACY OF GUSELKUMAB IN BIONAIVE PSORIATIC ARTHRITIS PATIENTS WITH SEVERE DISEASE ACTIVITY: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Authors: C. T. Ritchlin, E. Lubrano, M. S. Chimenti, E. Leibowitz, M. Sharaf, E. Rampakakis, F. Nantel, F. Lavie, A. Deodhar
Journal: Annals of the Rheumatic Diseases (2024)
POS1305 HLA-DRB1*11:01 ASSOCIATION DIFFERENCIATES ANTI-HMGCR IMMUNE-MEDIATED NECROTIZING MYOPATHY FROM NON-IMMUNE MEDIATED STATIN MYOTOXICITY
Authors: C. Corrales-Selaya, D. Prieto-Peña, J. G. Ocejo-Vinyals, A. Corrales Martinez, C. Garcia-Ibarbia, M. Martín Millán, Z. Salmón-García, V. Portilla González, N. Mota-Perez, M. Sebastián Mora-Gil, J. Batista-Liz, V. Pulito Cueto, R. Lopez-Mejías, R. Blanco, J. L. Hernández Hernández
Journal: Annals of the Rheumatic Diseases (2024)
POS1070 OSTEOARTICULAR X-RAY READING BY MEDICAL STUDENTS FOLLOWED BY EYE-TRACKING: BETTER UNDERSTANDING FOR BETTER TRAINING
Authors: A. Saraux, B. Quere, V. Laurier, M. Laurier, V. Devauchelle-Pensec, D. Guellec
Journal: Annals of the Rheumatic Diseases (2024)
AB0522 SELENIUM STATUS IN PATIENTS WITH RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND JUVENILE IDIOPATHIC ARTHRITIS
Authors: L. Wahl, T. S. Chillon, P. Seemann, S. Ohrndorf, R. Ochwadt, W. Becker, L. Schomburg, P. Hoff
Journal: Annals of the Rheumatic Diseases (2024)
POS0968 APREMILAST REDUCES INFLAMMATION AS MEASURED BY MRI, CLINICAL OUTCOMES, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM THE PHASE 4 MOSAIC STUDY
Authors: P. J. Mease, W. P. Maksymowych, M. Boesen, R. G. Lambert, G. Valenzuela, M. Bubb, O. Kubassova, F. Behrens, J. Reddy, S. Colgan, Y. Klyachkin, C. Deignan, Z. Zhou, M. Østergaard
Journal: Annals of the Rheumatic Diseases (2024)
POS1204 ANTI-CITRULLINATED HISTONE ANTIBODY CIT-013 TARGETS NETS IN INFLAMED JOINTS AND HALTS NET-MEDIATED JOINT DETERIORATION IN RA
Authors: S. Kumari, A. Kip, M. Van der Linden, J. Stein, T. Bruurmijn, M. Foster, P. Van Zandvoort, S. Van Dalen, H. Van Es, E. Meldrum, R. Chirivi
Journal: Annals of the Rheumatic Diseases (2024)
POS0981 ANALYZING OUTCOMES IN PSORIATIC ARTHRITIS: A COMPARATIVE STUDY BETWEEN JAK INHIBITORS AND INTERLEUKIN 17 INHIBITORS
Authors: R. Ali, H. Al-Sudani, I. Tskhakaia, S. Abdollahi, F. Rodriguez, A. Lau, I. Tan
Journal: Annals of the Rheumatic Diseases (2024)